Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines. Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The FDA implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real-world evidence. They promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, Forbes, and The Washington Post. He has held editorial positions with The British Medical Journal and The Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and 2019. Modern Healthcare named him amongst the “Most Influential Physician Executive and Leaders” in 2018, 2019, and 2020. TIME magazine named him one of its “50 People Transforming Healthcare” in 2018.
The Restaurant Finance & Development Conference is November 8-10 and registration is now open!